Johnson & Johnson to pay plaintiff in new Risperdal case
Posted on Tuesday, December 29th, 2015 at 11:24 am by Williams Hart | Updated: Tuesday, September 25th, 2018 at 9:15 pm
Janssen Pharmaceuticals Inc., a division of Johnson & Johnson, was ordered to pay a plaintiff $500,000 by a Philadelphia jury on December 11, according to news sources. Plaintiff Timothy Stange, who started taking the anti-psychotic drug Risperdal when he was 11, was awarded in the verdict after he said that the pharmaceutical company did not warn him of the side effects associated with the drug.
Stange was prescribed Risperdal to control his Tourette syndrome, but he developed gynecomastia during the three years he spent on the medication. Gynecomastia is a condition in which male breasts become enlarged; it has been cited as a side effect in many Risperdal lawsuits throughout the country.
This is the first Risperdal case to result in a settlement of less than $1 million, and Stange’s lawyer stated that the effect of the gynecomastia was “modest,” as it mostly affected his social life by causing the young boy humiliation.
If you have developed gynecomastia after taking Risperdal, please contact our qualified pharmaceutical defect attorneys at Williams Hart by calling us today at (713) 352-7071.